RT Journal Article
SR Electronic
T1 Protocol for a prospective, hospital-based registry of pregnant women with SARS-CoV-2 infection in India: PregCovid Registry study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.21.21260823
DO 10.1101/2021.07.21.21260823
A1 Gajbhiye, Rahul K
A1 Mahajan, Niraj N
A1 Waghmare, Rakesh
A1 Surve, Suchitra
A1 Howal, Prashant
A1 Bhurke, Aishwarya
A1 Pious, Merlin
A1 Modi, Deepak N
A1 Mahale, Smita D
YR 2021
UL http://medrxiv.org/content/early/2021/07/23/2021.07.21.21260823.abstract
AB Introduction Pregnant women are at increased risk of contracting coronavirus disease 2019 (COVID-19) due to several factors and therefore require special attention. However, the consequences of the COVID-19 pandemic on pregnant women and their newborns remain uncharted. The PregCovid registry aims to document the impact of SARS-CoV-2 infection on pregnant, post-partum women and their newborns. The aim of the registry is also to determine mother-to-child transmission of SARS-CoV-2 infection in India.Methods and analysis PregCovid is a hospital-based registry for capturing information of pregnant, post-partum women with COVID-19 and their newborns in India. Medical case records of pregnant and post-partum women with laboratory-confirmed diagnoses of COVID-19 will be captured in real-time using an online electronic patient record (EPR) software. The frequency of each symptom will be calculated. The laboratory data will be analyzed for calculating the frequency of laboratory parameters consistently higher in women with COVID- The adverse pregnancy and neonatal outcomes will be analyzed and their frequency will be calculated. Response to treatment will be analyzed for frequency calculation (number of women treated with different treatment regimens). The mother-to-child transmission data will be analyzed from the RT-PCR and/ antibody data of neonatal and maternal samples tested wherever the information is available. The registry data will be crucial for developing strategies for reducing the adverse impact of COVID-19 on pregnant women and their new-born.Ethics and dissemination The study is approved by the Institutional Ethics Committee of ICMR-National Institute for Research in Reproductive Health (#55/2020), BYL Nair Hospital, Mumbai, India (# 63/2020); and all the 18 participating study sites under Medical Education and Drugs Department of Government of Maharashtra. The Institutional Ethics Committees granted a waiver of consent as the data is collected from the medical case records.Trial registration number CTRI/2020/05/025423Strengths and limitations of this studyThe PregCovid registry is a hospital-based registry at dedicated COVID-19 hospitals in India. The registry will help to identify new epidemiological, clinical characteristics, obstetrics outcomes associated with pregnant women and/post-partum women with COVID-19 in India. The study will also generate information on clinical presentations and outcomes of neonatal born to mothers with COVID-19 in India.PregCovid registry will provide evidence of mother to child transmission of SARS-CoV-2 infection in Indian womenThe evidence on unusual presentations of COVID-19 in pregnant and post-partum women will be generated.The follow-up of participants is only till the discharge from the hospital. Long-term follow-up is not included in the study.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCTRI/2020/05/025423Funding StatementPregCovid registry is supported by an intramural grant of ICMR-NIRRH (ICMR-NIRRH/RA/965/09/2020). Rahul K Gajbhiye is an awardee of the DBT Wellcome India alliance clinical and public health intermediate fellowship (Grant no. IA/CPHI/18/1/503933).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study is approved by the Institutional Ethics Committee of ICMR-National Institute for Research in Reproductive Health (#55/2020), BYL Nair Hospital, Mumbai, India (# 63/2020); and all the 18 participating study sites under Medical Education and Drugs Department of Government of Maharashtra. The Institutional Ethics Committees granted a waiver of consent as the data is collected from the medical case records.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing is not applicable as no datasets were generated and/or analyzed for this study.COVID-19Coronavirus disease 2019CTRIClinical Trial Registry of IndiaEPRElectronic patient recordIRBInstitutional Review BoardsMEDDMedical Education and Drugs DepartmentMCGMMunicipal Corporation of Greater MumbaiMERS-CoVMiddle East Respiratory SyndromeMoHFWMinistry of Health and family WelfarePRIORITYPregnancy Coronavirus Outcomes RegistrySARS-CoVSevere acute respiratory syndrome coronavirusSARS-CoV-2Severe acute respiratory syndrome coronavirus 2